Australia legalizes medical psychedelics – psilocybin and MDMA allowed for medical treatments

The Australian government has taken a bold step to improve the mental health of its citizens by allowing access to two breakthrough therapies in the form of psilocybin and MDMA. The rescheduling of these psychedelics aims to help people struggling with debilitating conditions like post-traumatic stress disorder (PTSD) and depression that have proven resistant to traditional treatments.

The Australian government has made a progressive decision to prioritize the mental well-being of its citizens by reclassifying psilocybin and MDMA under the country’s drug law. Although these substances are not made available for general use, they are now listed on Schedule 8 for therapeutic purposes so that authorized psychiatrists can prescribe them to patients in need. However, it is important to note that these drugs remain under the stricter Schedule 9 classification for unauthorized use.

The Australian Therapeutic Goods Administration (TGA) made a landmark announcement on Friday recognizing the urgent need for better options to treat certain treatment-resistant mental illnesses. The decision underscores the urgent issue of the limited options available to patients and marks a significant step towards improving their mental well-being. The TGA said in its announcement that this is a critical step in addressing the currently unmet medical needs of those struggling with these debilitating conditions.

From July 1st, psilocybin and MDMA will be accessible in a controlled medical setting for therapeutic use, as stated by the Australian Therapeutic Goods Administration (TGA). The decision was the result of numerous requests for reclassification of the substances in the Poisons Standard, public consultation, a thorough report by an expert panel and the guidance of the Drug Planning Advisory Committee. However, the TGA also recognizes the inherent vulnerability of patients undergoing psychedelics-assisted psychotherapy and has put in place the necessary controls to protect them during the process.

However, the Australian Therapeutic Goods Administration (TGA) has not evaluated any products containing psilocybin or MDMA for their quality, safety, and effectiveness. Nonetheless, this amendment allows authorized psychiatrists to legally administer their patients a designated “unlicensed” drug containing these substances for certain therapeutic purposes. This change represents a significant milestone in improving access to innovative treatments for people struggling with mental illness.

Australia sets the pace

The recent policy change in Australia has been hailed by supporters in the United States and around the world. The Food and Drug Administration’s (FDA) designation of MDMA and psilocybin as breakthrough therapies only adds to the excitement surrounding this development. Rick Doblin, executive director of the US-based Multidisciplinary Association for Psychedelic Studies, expressed hope that this move will inspire other countries to follow suit and offer suffering people more opportunities to access novel treatments. He further emphasized that access to psychedelic therapies and comprehensive drug policy reform should be a global conversation and collaboration.

California Senator Scott Wiener, who was a driving force behind legislation legalizing the possession of certain psychedelics, hailed the news as “fantastic.”

However, the road to accessing psychedelics in the US was not easy. The Drug Enforcement Administration (DEA) recently denied a petition to postpone psilocybin’s plan and a doctor’s request for a federal waiver on the procurement and administration of the psychedelic to terminally ill patients. This has led to a number of lawsuits in federal courts. Sunil Aggarwal, a Washington state palliative care specialist, has been fighting the DEA for over a year to gain access to psilocybin. Despite his best efforts, the DEA denied his request to place the substance on a lower medication schedule and the doctor’s request for a waiver under the federal Right to Try (RTT) law.

Matt Zorn, a lawyer working on the case, said in a blog post that the process through which Australia’s reform took place is exactly what they want to achieve in their lawsuit against the DEA.

DEA faces more pressure

Under increasing pressure from bipartisan lawmakers, the Drug Enforcement Administration (DEA) has come under increased scrutiny over its stance on psychedelics like psilocybin. This has led to a series of congressional actions to clarify the use of these substances in medical treatments. It includes introducing accompanying legislation in the House and Senate to reaffirm that the Right to Try (RTT) directive includes Schedule I drugs such as psilocybin.

The proposed change would bring about a technical change to the existing law. It clarifies that terminally ill patients can use investigational drugs that have undergone clinical trials, regardless of their planning status, provided they have their doctor’s approval. This follows a letter from bipartisan congressmen, led by Rep. Earl Blumenauer (D-OR), calling on the DEA to allow terminally ill patients to use psilocybin without fear of federal prosecution.

Amid the spate of research uncovering the therapeutic benefits of psychedelics, Sen. Brian Schatz (D-HI) and Sen. Cory Booker (D-NJ) have taken a stand to highlight the potential of these substances. Although psilocybin and MDMA are labeled as Schedule I drugs, which limits research and development, they have shown remarkable results in treating PTSD, trauma, anxiety, and depression.

However, the federal ban has hampered study of these substances. To address the issue, Sen. Booker released a video in October in which he spoke about the limitations placed on psychedelics and the need to advance their research.

Diploma

With the Australian government’s recent decision to move psilocybin and MDMA to therapeutic use, the world is beginning to realize the immense potential of these substances to treat mental illness. This move underscores the need to rethink current drug policies and regulations to provide better care for patients with PTSD and other treatment-resistant mental health conditions.

As more studies point to the effectiveness of psychedelics in treating mental health disorders, pressure continues to mount on countries to reevaluate their stance on these substances. The future of psychedelics in medicine looks brighter. Hopefully this change in Australia will inspire other nations to follow suit and give suffering people access to the treatments they desperately need.

MORE ABOUT LEGALIZING AUSTRALIA, READ MORE…

AUSTRALIA PLANS TO EXPORT TONS OF WEED, READ THIS!